Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

Original languageEnglish
Article numbere83266
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 23 2013

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders'. Together they form a unique fingerprint.

Cite this